HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

<p class="MsoNormal">Featuring an interview with Dr Erika Hamilton, including the following topics:</p> <ul> <li>General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)</li> <li>Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11)</li> <li>Mechanisms of resistance to endocrine therapy (10:08)</li> <li>Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26)</li> <li>Other applications for PROTACs (24:24)</li> <li>Emerging data from the Phase III evERA trial (27:38)</li> <li>Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51)</li> </ul> <p class="MsoNormal"><a href= "http://m.researchtopractice.com/HRPosmBCPROTAC25/Video">CME information and select publicatio...